T2 Biosystems (NASDAQ:TTOO) received a $8.00 price objective from HC Wainwright in a note issued to investors on Monday. The firm presently has a “buy” rating on the medical equipment provider’s stock. HC Wainwright’s price target indicates a potential upside of 81.41% from the stock’s current price.
A number of other analysts have also recently issued reports on the company. Goldman Sachs Group assumed coverage on T2 Biosystems in a research report on Monday, January 29th. They issued a “neutral” rating and a $5.20 price objective for the company. Zacks Investment Research cut T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 price objective on shares of T2 Biosystems in a research report on Monday, October 30th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $5.56.
T2 Biosystems (NASDAQ:TTOO) traded up $0.13 on Monday, hitting $4.41. The stock had a trading volume of 111,062 shares, compared to its average volume of 255,095. T2 Biosystems has a 52 week low of $2.50 and a 52 week high of $6.99. The firm has a market capitalization of $153.33, a PE ratio of -2.32 and a beta of 1.71. The company has a debt-to-equity ratio of 2.25, a quick ratio of 5.28 and a current ratio of 5.40.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/12/t2-biosystems-ttoo-pt-set-at-8-00-by-hc-wainwright.html.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.